Every claim, every source.

This Cleveland Clinic-affiliated study followed 1,403 patients who were eligible for a protein-sparing modified fast program over 5 years to answer the question the original 1970s PSMF literature could not: does the dramatic short-term weight loss persist? Of those eligible, 879 (63 percent) actually initiated PSMF; the remaining 524 (37 percent) pursued other dietary approaches and served as a comparison cohort. The 1-year outcomes were dramatic and favored PSMF: -7.6 percent body weight in the PSMF arm versus -1.8 percent in the comparison arm, a 5.8-percentage-point difference (p less than 0.01). At 3 years, PSMF still showed an advantage but smaller: -2.3 percent vs -0.9 percent, a 1.4-point difference. By 5 years, the difference had effectively disappeared: -1.4 percent vs -1.0 percent (p=0.64, not statistically significant). The proportion achieving clinically meaningful (≥5 percent) weight loss told the same story: PSMF was strongly favored at 1 and 3 years, equivalent at 5 years. The honest conclusion: PSMF produces substantial short-term weight loss with good durability through year 3, but by year 5 the advantage over conventional dietary care is gone.

This Cell Metabolism paper combined a large NHANES-based human cohort (2,253 adults followed over 18 years) with mouse experiments to ask whether high protein intake — especially animal protein — drives cancer and mortality risk via IGF-1 and growth-hormone signalling. The headline finding is age-dependent. In adults aged 50–65, those reporting high protein intake (≥20 percent of calories from protein) had a 75 percent higher overall mortality and a fourfold higher cancer death risk over the next 18 years compared to low-protein eaters (under 10 percent of calories). The effect was largely abolished when the protein came from plant sources rather than animal sources. After age 65, the relationship reversed: high protein became protective for cancer and overall mortality — though high protein at any age was associated with a fivefold increase in diabetes mortality. Mouse experiments supported the mechanism: high-protein diets accelerated tumour growth and elevated IGF-1, while protein restriction did the opposite. The interpretation is that protein's relationship with longevity is not monotonic; it depends on age, on the protein source, and on what's being optimized for.

This Aging Cell paper directly addressed a paradox: rodent studies of caloric restriction reliably show IGF-1 reductions and longevity benefits, but the few existing human CR studies had not replicated the IGF-1 effect. Why? Fontana and colleagues compared three groups of human subjects: 28 long-term Calorie Restriction Society members (about 30 percent CR for 5+ years, but maintaining typical Western protein percentages around 24 percent of energy), 28 age-matched moderately protein-restricted vegans (around 10 percent of energy from protein), and 28 sedentary controls. The headline finding overturned the assumption that calories drive the IGF-1 effect: the strict CR group had no significant reduction in IGF-1 versus controls, while the vegans (heavier than the CR group, with more body fat) had significantly lower total and free IGF-1. The paper's conclusion is unambiguous: in humans, low protein intake — not low calorie intake — is what suppresses IGF-1. This finding helped explain why CR-induced longevity benefits in mice have not translated cleanly to humans on standard Western protein intakes, even at low calorie levels.

This 1980 Italian study addressed a specific operational question in PSMF design: how much protein is enough to spare nitrogen during severe caloric restriction? Twenty-five severely obese patients (16 women, 9 men) were assigned to one of four 4-week conditions: total fasting; an 80 kcal-PSMF (about 17 g protein per day); a 180 kcal-PSMF (about 40 g protein per day); or an alternating 80/180 kcal regimen. The researchers measured weight loss and nitrogen balance carefully across all four protocols. Both PSMF arms produced rapid weight loss comparable to total fasting, but the higher-protein conditions (40 g/day, with or without the lower-protein alternating phases) produced substantially less negative nitrogen balance. Nitrogen loss was significantly reduced from the third week of treatment onward, demonstrating that the metabolic adaptation that protects body protein takes time to engage and that adequate protein intake during that window matters disproportionately. The paper helped establish dose-response thinking in PSMF protocols — protein intake is not a binary "supplemented vs not" variable but a graded one with thresholds.

This 1978 JAMA paper by Bruce Bistrian is the canonical clinical introduction of the protein-sparing modified fast (PSMF). PSMF was developed by Bistrian and George Blackburn at Harvard in the early 1970s as a safer alternative to the total-starvation diets that were popular for severe obesity at the time. The protocol replaces calories with high-quality protein — typically around 1.2 to 1.5 grams per kilogram of ideal body weight — plus vitamin and mineral supplementation, allowing the patient to remain in nutritional ketosis while preserving lean body mass much more effectively than a water-only fast. The paper synthesizes the early clinical experience with this approach: rapid weight loss with substantially less muscle loss than total fasts produced, and reasonable tolerability in supervised clinical settings. Bistrian's clinical framework — protein as the spare, total-calorie restriction, supplementation, supervision — is the framework most modern PSMF protocols and protein-led short fasts (including the Sardine Protocol's mechanism) descend from.

This 1977 JAMA paper documents one of the earliest large-scale outpatient applications of the protein-sparing modified fast. Vertes, Genuth, and Hazelton at Case Western Reserve / Cleveland Clinic ran 519 severely obese outpatients through a supervised supplemented fasting program based on the protein-sparing principle Bistrian and Blackburn had recently established. The headline outcomes: 78 percent of patients lost a minimum of 18.2 kg (40 lb) during treatment. The overall weight-loss rate averaged 1.5 kg per week — 1.3 kg/week for women, 2.1 kg/week for men, reflecting the typical sex difference in baseline lean mass and metabolic rate. Most patients maintained normal daily activities throughout treatment with no serious adverse effects reported. The paper was a major demonstration that a structured very-low-calorie protocol with high-quality protein supplementation could be delivered safely in primary-care settings without the inpatient hospitalization that earlier total-fasting protocols required. It established the operational model that subsequent commercial and clinical PSMF programs (Optifast, HMR, the modern Cleveland Clinic protocol) would adopt.

George Cahill's 1970 NEJM review remains the single most important paper ever written on human starvation metabolism. Drawing on his lab's careful in-patient studies of obese volunteers undergoing therapeutic fasts (then a common obesity treatment), Cahill mapped the day-by-day fuel transitions that allow humans to survive weeks-to-months of food deprivation: the shift from glucose to fatty acid oxidation in muscle within hours of the last meal, the rise of hepatic ketogenesis over the first few days, and — most consequentially — the progressive switch by the brain from preferring glucose to preferring β-hydroxybutyrate and acetoacetate as primary fuels. This brain-ketone adaptation is what protects body protein. Without it, prolonged fasting would deplete muscle within days through gluconeogenesis demand; with it, daily protein loss falls to a trickle, fat becomes the dominant fuel, and survival extends to the limits of fat reserves. The paper identifies insulin as the principal regulatory hormone of the transitions and remains the foundational citation for almost every modern paper on fasting physiology.